Research & Development
Diplomat Pharmacy to supply CABOMETYX with expanded indication
16 January 2018 -

Diplomat Pharmacy Inc (NYSE: DPLO), an independent provider of specialty pharmacy services, is supplying Exelixis' limited-distribution treatment CABOMETYX (cabozantinib), now with an expanded indication, it was reported yesterday.

The product has been approved by the US Food and Drug Administration (FDA) as a first-line therapy indicated to treat patients with advanced renal cell carcinoma (RCC). It was initially approved as a second-line therapy for advanced RCC in 2016.

Joel Saban, Diplomat president, said, 'In supporting patients with advanced renal cell carcinoma, we are pleased to offer CABOMETYX as a new first-line treatment option. CABOMETYX tablets offer an important new alternative for patients seeking therapy options in the first-line setting and beyond."